Key result
Cross-neutralizing human anti-poliovirus antibodies bind the cellular receptor CD155 recognition site on serotypes 1 and 2, but have insufficient affinity to effectively neutralize type 3.
Population
Poliovirus virions (serotypes 1, 2, and 3) and human/chimpanzee anti-poliovirus antibodies
Design
Preclinical
Authors
Loading...
May guide cross-serotype antibody optimization; leaves open whether affinity maturation enables type 3 neutralization in vivo.
Cross-neutralizing anti-poliovirus antibodies bind the cellular receptor recognition site, suggesting potential for developing a universal neutralizing antibody.
Chen et al. (2013) studied Poliovirus. Cross-neutralizing human anti-poliovirus antibodies was evaluated on Epitope mapping and binding site identification. Cross-neutralizing human anti-poliovirus antibodies bind the cellular receptor CD155 recognition site on serotypes 1 and 2, but have insufficient affinity to effectively neutralize type 3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: